DNA methylation dysregulation is one of the hallmarks of diseases such as cancer (Baylin and Jones, 2016), and MeCP2 mutations can alter the reading of this mark, as in RTT (Kriaucionis and Bird, 2003), where it can impact the normal activity of cells. This evidence concerns the gene MECP2 and cancer.